Split the company?
probably premature at this point, but assuming (like we all are) the bladder cancer treatment gets the results we expect, would it be smart for TLT to split the cancer treatment part of the company and the vaccine part? Just thinking out loud, but with laser therapy and cancer treatment and vaccine/virus treatment TLT may be getting a bit confusing for the market. It also might maximize profits as each part has incredible potential on its own. Thoughts? (sorry if this has already been discussed)